Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD

Top Quote Results from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 (glycopyrronium bromide) 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo (p End Quote
  • (1888PressRelease) July 01, 2011 - Further efficacy and safety results from GLOW2 will be presented at a scientific congress in 2012, and the data will be used to support an application for regulatory approval to be filed before the end of 2011.

    * GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information